The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
1-ethyl-5-(3-(4-(3-hydroxy-3-methylbutoxy)-3-methylphenyl)pentan-3-yl)-N-(3-morpholinopropyl)-1H-pyrrole-2-carboxamide ID: ALA4777179
PubChem CID: 162643887
Max Phase: Preclinical
Molecular Formula: C31H49N3O4
Molecular Weight: 527.75
Molecule Type: Unknown
Associated Items:
Names and Identifiers Canonical SMILES: CCn1c(C(=O)NCCCN2CCOCC2)ccc1C(CC)(CC)c1ccc(OCCC(C)(C)O)c(C)c1
Standard InChI: InChI=1S/C31H49N3O4/c1-7-31(8-2,25-11-13-27(24(4)23-25)38-20-15-30(5,6)36)28-14-12-26(34(28)9-3)29(35)32-16-10-17-33-18-21-37-22-19-33/h11-14,23,36H,7-10,15-22H2,1-6H3,(H,32,35)
Standard InChI Key: WLJIEACJNZCWQI-UHFFFAOYSA-N
Molfile:
RDKit 2D
38 40 0 0 0 0 0 0 0 0999 V2000
32.5747 -18.4790 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.9913 -19.1956 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.4036 -18.4765 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.8524 -18.3706 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.8511 -19.1979 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
36.5660 -19.6108 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.2824 -19.1975 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.2795 -18.3669 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
36.5642 -17.9579 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
36.5658 -20.4358 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.1364 -19.6099 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
37.9925 -17.9518 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.7085 -18.3616 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.8015 -19.1806 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
39.6091 -19.3491 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
40.0189 -18.6331 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
39.4645 -18.0222 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
40.8410 -18.5435 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.3285 -19.2091 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
41.1737 -17.7886 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
37.4037 -17.3623 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.5746 -17.3623 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.4150 -16.5668 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.4410 -16.5656 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.9938 -17.6992 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
42.3265 -16.9443 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.4222 -19.1968 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.7075 -19.6088 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.2786 -19.6076 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
39.6332 -17.2146 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
40.4169 -16.9569 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
43.1465 -16.8548 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
43.4793 -16.0999 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
44.3004 -16.0130 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
44.6335 -15.2621 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
44.1492 -14.5938 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
43.3279 -14.6813 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
42.9908 -15.4371 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2 1 1 0
3 2 1 0
4 5 2 0
5 6 1 0
6 7 2 0
7 8 1 0
8 9 2 0
9 4 1 0
6 10 1 0
5 11 1 0
8 12 1 0
12 13 1 0
13 14 2 0
14 15 1 0
15 16 2 0
16 17 1 0
17 13 1 0
18 19 2 0
18 20 1 0
16 18 1 0
12 21 1 0
12 22 1 0
22 23 1 0
21 24 1 0
20 25 1 0
25 26 1 0
11 27 1 0
27 28 1 0
28 2 1 0
2 29 1 0
17 30 1 0
30 31 1 0
26 32 1 0
32 33 1 0
33 34 1 0
33 38 1 0
34 35 1 0
35 36 1 0
36 37 1 0
37 38 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 527.75Molecular Weight (Monoisotopic): 527.3723AlogP: 4.91#Rotatable Bonds: 14Polar Surface Area: 75.96Molecular Species: NEUTRALHBA: 6HBD: 2#RO5 Violations: 1HBA (Lipinski): 7HBD (Lipinski): 2#RO5 Violations (Lipinski): 1CX Acidic pKa: ┄CX Basic pKa: 7.03CX LogP: 4.40CX LogD: 4.25Aromatic Rings: 2Heavy Atoms: 38QED Weighted: 0.34Np Likeness Score: -0.90
References 1. Kang Z,Wang C,Tong Y,Li Y,Gao Y,Hou S,Hao M,Han X,Wang B,Wang Q,Zhang C. (2021) Novel Nonsecosteroidal Vitamin D Receptor Modulator Combined with Gemcitabine Enhances Pancreatic Cancer Therapy through Remodeling of the Tumor Microenvironment., 64 (1.0): [PMID:33381963 ] [10.1021/acs.jmedchem.0c01197 ]